Table 4.
Summary of sensitivity analyses
| No of patients | Adjusted incidence rate ratio (95% confidence intervals)* | ||||
|---|---|---|---|---|---|
| Pretreatment | Antipsychotic drug alone | Cholinesterase inhibitor alone | Combination | ||
| Main analysis | 15 278 | 6.17 (5.69 to 6.69) | 1.33 (1.24 to 1.43) | 1.17 (1.10 to 1.24) | 1.35 (1.26 to 1.45) |
| Grouped by sex and age: | |||||
| Men | 5088 | 7.63 (6.73 to 8.65) | 1.55 (1.38 to 1.75) | 1.18 (1.06 to 1.30) | 1.48 (1.31 to 1.67) |
| Women | 10 190 | 5.35 (4.80 to 5.95) | 1.24 (1.13 to 1.35) | 1.16 (1.07 to 1.25) | 1.29 (1.18 to 1.41) |
| Age group 65-74 | 3137 | 2.81 (2.03 to 3.90) | 1.56 (1.25 to 1.93) | 1.16 (0.95 to 1.40) | 1.67 (1.29 to 2.16) |
| Age group 75-84 | 8703 | 6.11 (5.49 to 6.80) | 1.28 (1.17 to 1.41) | 1.18 (1.09 to 1.28) | 1.25 (1.14 to 1.37) |
| Age group ≥85 | 3438 | 8.07 (7.03 to 9.26) | 1.20 (1.05 to 1.37) | 1.29 (1.15 to 1.45) | 1.51 (1.33 to 1.72) |
| Grouped by anticholinergic burden indicators: | |||||
| Anticholinergic drug scale ≥2 | 6579 | 7.41 (6.60 to 8.33) | 1.76 (1.60 to 1.95) | 1.35 (1.24 to 1.48) | 1.67 (1.51 to 1.85) |
| Anticholinergic drug scale 0-1 | 8699 | 5.30 (4.74 to 5.94) | 1.02 (0.93 to 1.13) | 1.05 (0.96 to 1.13) | 1.11 (1.01 to 1.23) |
| Grouped by cumulative dose of antipsychotic drugs: | |||||
| Higher than median value | 3232 | 5.73 (4.54 to 7.24) | 3.80 (3.38 to 4.27) | 2.04 (1.77 to 2.35) | 5.38 (4.79 to 6.05) |
| Equal to or lower than median value | 3247 | 5.45 (4.54 to 6.53) | 2.91 (2.54 to 3.33) | 1.66 (1.48 to 1.87) | 2.12 (1.82 to 2.47) |
| Restricted to outcomes at outpatient settings only | 7914 | 2.54 (2.14 to 3.01) | 1.12 (1.01 to 1.25) | 1.09 (1.00 to 1.19) | 1.02 (0.91 to 1.13) |
| Re-selected patients without excluding schizophrenia and bipolar disorder | 15 791 | 6.07 (5.60 to 6.57) | 1.32 (1.24 to 1.42) | 1.17 (1.10 to 1.24) | 1.33 (1.24 to 1.43) |
| Grouped by schizophrenia (yes) | 98 | 2.94 (0.70 to 12.37) | 1.55 (0.80 to 2.99) | 0.66 (0.16 to 2.72) | 1.79 (0.75 to 4.28) |
| Grouped by schizophrenia (no) | 15 693 | 6.08 (5.61 to 6.59) | 1.32 (1.23 to 1.42) | 1.17 (1.10 to 1.24) | 1.33 (1.24 to 1.43) |
| Grouped by bipolar disorder (yes) | 426 | 3.24 (1.76 to 5.99) | 1.12 (0.80 to 1.58) | 1.19 (0.79 to 1.81) | 0.84 (0.55 to 1.30) |
| Grouped by bipolar disorder (no) | 15 365 | 6.15 (5.67 to 6.67) | 1.33 (1.24 to 1.43) | 1.17 (1.10 to 1.24) | 1.35 (1.26 to 1.45) |
| Grouped by depression (yes) | 4743 | 4.13 (3.49 to 4.90) | 1.12 (1.00 to 1.27) | 1.03 (0.91 to 1.16) | 1.06 (0.93 to 1.20) |
| Grouped by depression (no) | 11 048 | 6.95 (6.34 to 7.61) | 1.43 (1.32 to 1.56) | 1.22 (1.14 to 1.31) | 1.48 (1.37 to 1.61) |
| Removed patients who died during study period | 10 080 | 6.43 (5.80 to 7.12) | 1.25 (1.15 to 1.37) | 1.10 (1.02 to 1.19) | 1.18 (1.08 to 1.30) |
| Removed patients who died within three months after events | 15 014 | 6.12 (5.63 to 6.64) | 1.30 (1.21 to 1.40) | 1.17 (1.10 to 1.24) | 1.31 (1.22 to 1.41) |
| Redefined outcome by specific codes, all events | 5458 | 10.16 (9.10 to 11.35) | 1.52 (1.36 to 1.69) | 1.22 (1.11 to 1.35) | 1.67 (1.49 to 1.87) |
| Falls | 621 | 10.77 (8.19 to 14.16) | 1.26 (0.91 to 1.74) | 0.87 (0.65 to 1.16) | 1.49 (1.09 to 2.04) |
| Fractures | 5149 | 10.41 (9.29 to 11.66) | 1.57 (1.40 to 1.76) | 1.26 (1.13 to 1.39) | 1.70 (1.51 to 1.91) |
| All episodes of falls and fractures | 15 278 | 5.53 (5.21 to 5.88) | 1.24 (1.18 to 1.31) | 1.16 (1.11 to 1.21) | 1.31 (1.25 to 1.38) |
| Redefined the length of pretreatment period to: | |||||
| 7 days before treatment | 15 278 | 9.49 (8.64 to 10.43) | 1.30 (1.21 to 1.39) | 1.17 (1.10 to 1.25) | 1.32 (1.23 to 1.42) |
| 21 days before treatment | 15 278 | 4.91 (4.56 to 5.30) | 1.34 (1.25 to 1.44) | 1.17 (1.10 to 1.24) | 1.37 (1.27 to 1.47) |
| 28 days before treatment | 15 278 | 4.43 (4.14 to 4.75) | 1.35 (1.26 to 1.45) | 1.18 (1.11 to 1.25) | 1.39 (1.29 to 1.49) |
| Focus on individual antipsychotic drugs: | |||||
| Haloperidol | 4745 | 12.11 (10.84 to 13.54) | 3.75 (3.15 to 4.47) | 1.16 (1.06 to 1.27) | 4.26 (3.37 to 5.37) |
| Risperidone | 5119 | 2.74 (2.23 to 3.35) | 1.15 (0.99 to 1.35) | 1.23 (1.13 to 1.35) | 1.32 (1.13 to 1.54) |
| Olanzapine | 1314 | 3.72 (2.57 to 5.37) | 1.35 (1.00 to 1.82) | 1.31 (1.09 to 1.56) | 1.77 (1.31 to 2.39) |
| Quetiapine | 12 851 | 5.40 (4.91 to 5.93) | 1.16 (1.07 to 1.26) | 1.18 (1.11 to 1.26) | 1.16 (1.07 to 1.26) |
Combination=combination of cholinesterase inhibitors and antipsychotic drugs.
*
Reference group=non-treatment period.